MR. 1995. In vivo cultivation of tumor cells in hollow fibers. Life Sci 57(2):131–41.


Johnson DI, Decker S, Zaharevitz D, et al. 2001. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84(10):1424–31.

Johnson JR, Williams G, Pazdur R. 2003. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21 (7):1404–11.

Justice RL. 1997. FDA role in cancer drug development and requirements for approval. Teicher BA, editor. Anticancer Drug Development Guide. Totowa, New Jersey: Humana Press. Pp. 293–304.


Khleif SN, Curt GA. 2000. Animal models in developmental therapeutics. Bast RC, Gansler TS, Holland JF, Frei E, Editors. Cancer Medicine. 5th ed. Hamilton, Ont.; Lewiston, NY: Decker. Pp. 573–584.


Levin, J, Schilsky, R, Burris, H, and et al. 2001. North American Phase III study of oral eniluracil (EU) plus oral 5 fluorouracil (5-FU) versus intravenous (IV) 5FU plus leucovorin (LV) in the treatment of advanced colorectal cancer. Proceedings of ASCO:23.


Mininberg, ED, Herbst, RS, Henderson, T, and et al. 2003. Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). ProcASCO:2521.

Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. 1997. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 12(7):533–41.


National Cancer Institute. 2005. Pursuing the Promise of Biomarkers. NCI Cancer Bulletin 2(5):1.

National Cancer Institute. 2005. Cancer Research and Regulatory Fellowships Announced. NCI Cancer Bulletin 2(8):16

NCCN National Comprehensive Cancer Network. Clinical Trials Information, accessed October 10, 2003. Web Page. Available at: http://www.nccn.org/.


Pardoll D. Presentation to the Committee on Shortening the Time Line for New Cancer Treatments. Washington, D.C.: 2002.

Pardoll, D. 2002a. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2(4):227–38

Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. 1989. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14):1088–92.

Pazdur, R. 2000. Response Dates, Survival, and Chemotherapy Trials. J. Natl. Cancer Inst. 92(14):1552–3

Petricoin, EF, Zoon, KC, Kohn, EC, et al. 2004. Clinical Proteomics: Translating Benchside Promise into Bedside Reality. Nature Reviews Proteomics Collection, September:20–32

Plaister MK. Letter to Honorable Thomas J Bliley Jr, Chairman Committee on Commerce House of Representatives. 2000 June 13.

Plowman J, Dykes BS, Hollingshead M et al., 1997 Human tumor xenograft models in



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement